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Summary
Background Although an association of occurrence of
menopause and subsequent oestrogen deficiency with
increased cardiovascular disease has been postulated,
studies on this association have not shown convincing
results. We investigated whether age at menopause is
associated with cardiovascular mortality risk.
Methods We studied a cohort of 12 115 postmenopausal
women living in Utrecht, Netherlands, aged 50-65 years at
enrolment in a breast cancer screening project. During
follow-up of up to 20 years the women attended screening
rounds at which we asked questions on menopausal
status, age at menopause, medication use, cardiovascular
risk factors, and ovarian function. Deaths were ascertained
from the patient’s family physicians. Life-table analysis and
Cox regression analysis were used to investigate the
association between age at menopause and cardiovascular
mortality. All analyses were adjusted for biological age.
Findings 824 women died of cardiovascular causes. 1459
women had left the study area. The risk of cardiovascular
mortality was higher for women with early menopauses
than for those with late menopauses. The age-adjusted
hazard ratio of age at menopause was 0&middot;982 (95% Cl
0&middot;968-0&middot;996, p=0&middot;01)&mdash;ie, for each year’s delay in the
menopause the cardiovascular mortality risk decreased by
2%. The extra risk of early menopause seemed to decrease
with biological age (p for interaction 0&middot;07); at biological
age 60 the reduction of the annual hazard was 3%, but at
age 80 there was no reduction. Adjustment for known
cardiovascular risk factors and indicators of ovarian
function did not significantly alter the risk estimate.
Interpretation These results support the hypothesis that
longer exposure to endogenous oestrogens protects
against cardiovascular diseases. The effect of an early
menopause may be more important at younger biological
ages.
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Introduction
Premenopausal women seem to be protected against
cardiovascular morbidity and mortality in comparison
with men of similar age or postmenopausal women.’-’
Loss of ovarian function and subsequent deficiency of
endogenous oestrogens is suggested to promote
cardiovascular disease and death after menopause .4,1
If endogenous oestrogens protect against cardiovascular
disease, an early menopause might incur a higher risk,
because of lower exposure to oestrogens. Evidence for this
hypothesis has been inconclusive.6 Several investigations
had small sampless,7-9 and angina pectoris was used as the
endpoint in some.5,10,11 The two prospective studies that
have been done, the Framingham Heart Study2 and the
Nurses’ Health Study,3 were better designed to address
the question of whether the menopause itself is a risk
factor for cardiovascular disease than to show whether an
early menopause poses a particular risk. The main
problem of studies done so far is the short
postmenopausal follow-up period, which has probably
been too short for cardiovascular diseases to occur in
sufficient frequency for statistical analysis.
To explore the relation between the age at menopause
and subsequent cardiovascular mortality, we studied a
cohort of postmenopausal women aged 50-65 years at
enrolment in an experimental breast cancer screening
project in 1974-77; the women were followed up for a
median of 16 years (range 1-20 years).
Patients and methods
Patients
Between December, 1974, and September, 1977, 14 697 (72%)
of the 20 555 women born between 1911 and 1925, living in the
city of Utrecht, Netherlands, were enrolled in the DOM
Project.’2 The breast cancer screening was repeated several times
(maximum four; women dropped out between rounds). 2203 of
the women were within a year of their last menstrual period and
were deemed premenopausal. The remaining 12 494 reported
that menses had ceased at least 12 months previously, and they
were classified as postmenopausal. We excluded data for 1004 of
the 2203 premenopausal women for whom the age at menopause
could not be calculated from follow-up data, because they did
not attend further screening sessions. Data for 1199 women who
became menopausal during follow-up were included in the
analysis, starting from the year they became postmenopausal.
Data for 1578 women were excluded because of use of oestrogen
replacement therapy, and the self-reported age at menopause was
probably not reliable. Thus, 12 115 women were included in the
present analysis.
Municipal registries informed the Epidemiology Department
each month about moves and deaths of cohort members. At the
end of the follow-up period (Dec 31, 1994) 1459 women (12%
of the population) had moved outside the DOM area. The
median follow-up for these women was 10 years, with a
maximum of 20 years (whole cohort median 16, maximum 20
years). Cause of death was ascertained from the women’s general
practitioners. During the 20 years of follow-up (202 717 women-
years), 2022 women died, 824 of cardiovascular diseases, 726 of
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*Mean (SD). Other data are number (%). tMeasured in a subsample.
Table 1: Distribution of baseline cardiovascular risk factors
cancer, 94 from injury or external causes, including accidents
and suicides, and 378 from other causes.
Questionnaires on menopausal status, age at menopause,
medication use, cardiovascular risk factors, and indicators of
ovarian function were completed at each screening visit.
Menopause was defined as cessation of menstrual bleeding for at
least 12 months. Hypertension was defined as systolic blood
pressure of 160 mm Hg or more, diastolic blood pressure of
90 mm Hg or more, use of antihypertensive medication, or a
combination of these features. Women were classified as diabetic
if they reported use of oral hypoglycaemic drugs or insulin or
were on a diabetes diet. In the original questionnaire, previous or
present cardiovascular disease was recorded as ischaemic cerebral
attacks or myocardial infarction up to 5 years before the second
screening visit or use of medication for cardiovascular diseases.
This medication consisted of aminoglycosides, antiarrhythmic
drugs, nitrates, other antianginal drugs, or anticoagulants. Oral
contraceptive use was coded as never use or ever use in statistical
analyses, since the number of the women taking oral
contraceptives was too small for detailed analysis. Parity and age
at first delivery were classified in three categories-no children,
children before or at age 24, and children after age 24. Height,
weight, and subscapular and triceps skinfold thicknesses were
measured at the first screening visit. Body-mass index was
calculated and dichotomised at 30 kg/m2 or more. Skinfold
thicknesses were measured with callipers that could not measure
skinfolds thicker than 40 mm, so such skinfolds were coded as
40 mm on the original registration forms. The study population
was divided into subgroups by quintiles of subscapular as well as
triceps skinfolds, resulting in subgroups of women with equally
distributed fat, peripheral obesity, and upper-body obesity,
respectively. 13
Total cholesterol was measured in a sample of the population
(2179). Blood pressure measurements started only after the first
961 women had been screened, and are thus missing for those
women. This subgroup was large enough for these data to be
included as a separate category of the hypertension variable in
statistical analyses. Data on smoking and previous cardiovascular
diseases were collected at the second screening visit, 1-5 years
after the first visit, and are therefore not known for women who
did not attend the second screening (2458). These data are also
considered as separate categories in the statistical analysis.
The endpoint of the analysis was total cardiovascular mortality,
codes 390-459 of the International Classification of Diseases,
Ninth Revision (ICD-9). Death from other causes, loss to follow-
up due to moving outside the DOM area, and withdrawal from
the study were censoring events.
The association of age at menopause and cardiovascular
mortality was first assessed by annual hazard estimates for
biological ages between 50 and 80.14 Biological age was a
continuous variable, and age at menopause was classified in five
categories (<40, 40-44, 45-49, 50-54, >54). Annual hazards
were smoothed with a bandwidth of 5 years, and 95% CI were
calculated.
Cox regression analysis was used to quantify further the effect
of age at menopause on cardiovascular mortality. Since biological
age is a major risk factor for cardiovascular mortality, all analyses
were adjusted for age. This adjustment was done with biological
age as the time axis. Since age at entry varied between 50 and 65,
we had to account for left truncation of the data caused by the
staggered entry. Age at menopause was analysed as a continuous
variable, with the assumption of a linear relation between age at
menopause and cardiovascular mortality. This approach implies
that a menopause delay of 1 year has identical effects over the
entire range of menopause ages. We used a restricted cubic spline
Table 2: Annual hazards of cardiovascular mortatity for women
at biological ages 65, 70, and 75 in relation to age at
menopause
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Figure: Annual hazard of cardiovascular mortality (logarithmic
scale) in relation to age at menopause
For proportional hazards, the lines should be parallel.
function of age at menopause with three knots to test the linearity
assumption. The use of such a function has been proposed as a
statistically efficient procedure to detect non-linearity. 15 The Cox
model further assumes that the hazards are proportional over
time.
Proportionality of the effect of age at menopause was
examined graphically in a plot of the logarithm of the annual
hazards and was statistically tested by the addition to the Cox
model of the interaction term of age at menopause and biological
age. Because age at entry varied between 50 and 65, a cohort
effect may have confounded the association at issue. This was
approximated by year of birth. To study whether year of birth or
other known cardiovascular risk factors caused confounding, we
entered them first individually and then simultaneously into the
Cox model with age at menopause to see whether the crude
hazard ratio of age at menopause changed substantially. The
effects of age at menopause were investigated in predetermined
subgroups: women with different types of menopause (natural,
hysterectomy, oophorectomy, radiation/surgery type unknown),
and smokers and non-smokers. To test the significance of the
subgroup effects, interaction terms of age at menopause with
type of menopause and smoking were added to the Cox model,
respectively.
Results
Baseline characteristics were distributed similarly among
the strata of age at menopause (table 1). Oral
contraceptive use was rare among these women, who were
aged 37-52 when oral contraceptives were introduced in
the Netherlands.
The risk of cardiovascular mortality was higher at all
three biological ages analysed for women who had early
menopauses (table 2). For example, the annual hazard of
cardiovascular death at age 70 was 5-7% when the
menopause occurred at age 40-44 and 4-3% when
menopause occurred at age 55 or later. We quantified the
hazard ratio of age at menopause, adjusted for age, as
0-982 (95% CI 0-968-0-996). Thus, each year that the
menopause is delayed decreases the annual hazard of
cardiovascular death by 2%. For example, a woman with
menopause at age 45 has a risk of cardiovascular death
0-98 times that of a woman who has her menopause at
age 44.
The effect of age at menopause on cardiovascular
mortality was reasonably linear (p=035). This finding
Table 4: Relation of age at menopause with cardiovascular
mortality for subgroups of type of menopause and smoking
means that the difference in effect of age at menopause on
cardiovascular mortality between each pair of two
consecutive menopausal years is equal-ie, a menopause
delay of 1 year at age 40 has the same effect as a 1-year
delay at age 50.
The extra risk of cardiovascular mortality due to early
menopause seemed to decrease with increasing biological
age, although the difference had borderline significance
(p=007). The cardiovascular mortality risks clearly
differed among the age at menopause subgroups at
biological age 60, but they were more similar at age 80
(figure). The estimated effect of each year of delay in
menopause is a reduction in annual hazard of 3% for a
woman of biological age 65, 2% for a 70-year-old, 1% for
a 75-year-old, and no reduction for an 80-year-old.
Individually, none of the baseline variables influenced
the estimation of the average hazard ratio. The hazard
ratio adjusted for all variables simultaneously was 0-983
(95% CI 0-975-0-998) so confounding by known
cardiovascular risk factors is negligible (table 3). For
women who had undergone hysterectomy, age at
menopause was not associated with cardiovascular
mortality (table 4). By contrast, for those who had had
oophorectomy the effect might be stronger, although the
differences in these hazard ratios were not significant
(p for interaction 0-21). The hazard ratio for age at
menopause was 1-007 in smokers and 0-976 in non-
smokers, although again this difference was not significant
(p for interaction 0-22; table 4).
Discussion
Our results clearly show an increased risk of
cardiovascular mortality for women who have early
menopause. Biases may have led to incorrect effect
estimates. Selection bias could have led to an
underestimation. Women had to survive until at least age
50 to be invited for screening. Furthermore, they had to
be healthy enough to attend screening. Women who later
died of cardiovascular disease were more likely to
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withdraw between screening rounds. Thus, women
attending the first screening were probably at lower
cardiovascular risk. Reanalysis of the data including only
women who attended at least the second screening round,
however, gave similar results. Underestimation of the
effect of early menopause due to selection bias will
therefore be slight.
Although the study design was prospective, 85% of the
women were already postmenopausal at enrolment, which
could lead to misclassification bias. Age at menopause as
reported at the first screening round was compared with
that reported in the fifth round, 7-5 years later, in a
sample of 4892 women. For 80% of the sample the two
reports differed by at most 1 year; thus, misclassification
was limited. The findings are similar to those of the
Nurses’ Health Study. 16
Biased reporting and measurement of risk factors by
women with an early menopause is an unlikely
explanation for our results. Associations of type of
menopause, parity and age at first delivery, oral
contraceptive use, smoking behaviour, and body-mass
index with age at menopause have been reported
previously. 17-20 Hypertension, total cholesterol, body-fat
distribution, presence of diabetes, and previous
cardiovascular events are known risk factors for
cardiovascular mortality. Adjustment for potential
confounders was achieved by adding these factors
individually or simultaneously into the Cox model. For
parity we also checked whether the number of children
was a potential confounder, and found that it was not.
Information on lipoprotein fractions and subfractions was
not available. However, since lipid concentrations are
probably involved in the biological mechanism of the
effect of oestrogens on cardiovascular diseases, it would
be inappropriate to adjust for lipid concentrations.
Reanalysis of the data for women with complete data only
gave similar results for the estimated hazard ratios. The
possibility of ineffective adjustment caused by inclusion of
missing data as separate categories of variables can
therefore be excluded.
The effect of age at menopause on cardiovascular
mortality was absent for women who had undergone
hysterectomy and stronger for those who had had
oophorectomy. This difference, although not statistically
significant, is consistent with the postulated biological
mechanism that hysterectomy does not lead to immediate
cessation of oestrogen production, whereas oophorectomy
does.
Smoking advances the age of natural menopause by
about 1-5 years.21 The effect of age at menopause may be
expected to differ between smokers and non-smokers,
because smokers become menopausal even earlier.
Although the effect of age at menopause in the various
smoking subgroups did not differ significantly, the hazard
ratio of age at menopause was almost unity for smoking
women. The effect of smoking on cardiovascular
mortality seems to be so strong as to over-ride the effect
of an early menopause.
The evidence that reduced exposure to endogenous
oestrogens leads to increased cardiovascular morbidity has
mainly come from studies of postmenopausal exogenous
oestrogen replacement,6 for which a relative risk of 0-56
(95% CI 0-50-0-61) has been estimated.22 Morbidity and
mortality statistics suggest that the decrease in the gap
between cardiovascular morbidity and mortality in men
and women cannot be attributed to the menopause.9,23-25
Studies on the effect of endogenous oestrogens on the
occurrence of cardiovascular disease have been
inconclusive.2,5,26,27 The only prospective studies reported
inconsistent results.2,1 The Framingham Heart Study
reported higher risk of cardiovascular disease in
postmenopausal women that was even more pronounced
in women aged 40-44 years,2 whereas the Nurses’ Health
Study found no significant association with time since
natural menopause.3 In both cohorts, the women were
young for cardiovascular disease to occur, less than 55
and 61 years old, respectively, and the time from
menopause to cardiovascular disease may have been too
short to allow convincing results to be shown. By
contrast, in our study the oldest women were 85 years old
and the postmenopausal follow-up extended to a
maximum of 20 years.
The only investigation in which plasma concentrations
of oestrogens were measured did not show any association
with cardiovascular mortality. 27 However, plasma
concentrations were measured in postmenopausal women,
and such measurements do not necessarily reflect
premenopausal hormone concentrations.
In conclusion, our study provides evidence that early
menopause is an independent risk factor for
cardiovascular mortality and supports the hypothesis that
reduced endogenous oestrogen exposure increases
cardiovascular mortality risk. The effect of an early
menopause may be more important at younger biological
ages.
The study was supported by grant 92.361 from the Netherlands Heart
Foundation.
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Invasive pneumococcal disease in a cohort of predominantly
HIV-1 infected female sex-workers in Nairobi, Kenya
Charles F Gilks, Sylvia A Ojoo, Josephine C Ojoo, Richard J Brindle, John Paul, Barry I F Batchelor, Joseph N Kimari,
Robert Newnham, Joab Bwayo, Francis A Plummer, David A Warrell
Summary
Background HIV infection is a major risk factor for
pneumococcal disease in industrialised countries. Although
both are common infections in sub-Saharan Africa, few
studies have investigated the importance of this
interaction. We have followed up a cohort of female sex-
workers in Nairobi and report here on the extent of invasive
pneumococcal disease.
Methods A well-established cohort of low-class female sex-
workers, based around a community clinic, was followed up
from October, 1989, to September, 1992. 587 participants
were HIV positive and 132 remained HIV negative. Set
protocols were used to investigate common presentations.
Cases were identified clinically and radiographically.
Streptococcus pneumoniae and other pathogens were
diagnosed by culture.
Findings Seventy-nine episodes of invasive pneumococcal
disease were seen in the 587 HIV-positive women
compared with one episode in the 132 seronegative women
(relative risk 17&middot;8, 95% Cl 2&middot;5 to 126&middot;5). In seropositive
women the incidence rate was 42&middot;5 per 1000 person-years
and the recurrence rate was 264 per 1000 person-years.
By serotyping, most recurrent events were re-infection. A
wide spectrum of HIV-related pneumococcal disease was
seen: only 56% of cases were pneumonia; sinusitis was
seen in 30% of cases, and occult bacteraemia, a novel
adult presentation, in 11%. Despite forty-two bacteraemic
episodes, no deaths were attributable to Strep
pneumoniae. At first presentation the mean CD4 cell count
was 302/&micro;L (SD 191) and was 171/&micro;L (105) for recurrent
episodes. During acute Strep pneumoniae infection the
CD4 cell count was reversibly suppressed (mean fall in
sixteen episodes, 105/&micro;L [123]). The neutrophil response
to acute infection was blunted and was correlated with
CD4 count (r=0&middot;50, 95% Cl 0&middot;29 to 0&middot;66). Strep
pneumoniae caused more disease, at an earlier stage of
HIV immunosuppression, than Mycobacterium tuberculosis
or non-typhi salmonellae.
Interpretation Our study highlights the importance of the
pneumococcus as an early but readily treatable
complication of HIV infection in sub-Saharan Africa.
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Introduction
Sub-Saharan Africa currently bears the brunt of the HIV
epidemic.’ Most attention clinically has been given to the
interaction of HIV and Mycobacterium tuberculosis.
Surprisingly little is known about the importance of other
high-grade bacterial infections during HIV infection.2 In
Africa, lobar (pneumococcal) pneumonia is a leading
cause of hospital admission, particularly for young men.’
Although Streptococcus pneumoniae bacteraemia,4,5
pneumonia,6-9 and fatal meningitis’O are associated with
HIV infection, the extent of interaction is unclear. We
therefore studied the occurrence and clinical spectrum of
bacterial and mycobacterial diseases during HIV infection
in a cohort of female sex-workers in Nairobi. Here we
present our data on invasive pneumococcal disease in
particular.
Cohort and methods
Cohort
Between October, 1989, and September, 1992, we followed up
an established cohort of female sex-workers in Nairobi.
Recruitment to the cohort started in 1985 and connnues.
Women who live and work by selling sex in Pumwani, a poor
